文献速递生殖医学

长春新碱对儿童癌症患者睾丸发育和功能的影响

The impact of vincristine on testicular development and function in childhood cancer.
PubMed 文献 · Hum Reprod Update · 2023-01-01

本系统综述旨在评估含长春新碱方案对青春期前人类睾丸的影响及成年后睾丸功能和生育力。检索1900年1月1日至2021年3月5日文献,纳入24项研究(8%,n=7134名男性),其中9项有对照组,4项对长春新碱相对性腺毒性进行亚组分析。有限临床研究未显示青春期前暴露长春新碱后的性腺毒性作用,与近期啮齿动物研究结果相反。

要点

  • 24项研究(n=7134)中,无一项长春新碱亚组分析报告其与生育潜力呈负相关。
  • 最大对照研究(n=6224)中,长春新碱与生育风险比HR=0.56相关。
  • 一项研究(n=143)亚组分析显示,包括长春新碱在内的有丝分裂抑制剂与健康对照相比精液分析无显著差异。

核心结论

  • 与近期啮齿动物研究结果相反,有限的临床研究未显示青春期前暴露长春新碱后的性腺毒性作用。
  • 鉴于缺乏长春新碱亚组分析的数据,需要使用人类睾丸组织进行长春新碱暴露的实验研究。
  • 此类研究结果可更好地告知儿童癌症患者其未来生育力及治疗开始前生育力保存的资格。

研究设计与样本

  • 系统综述,按照PRISMA指南进行文献系统检索,研究注册于PROSPERO。
  • 检索PubMed和Scopus中1900年1月1日至2021年3月5日发表的英文文章,检索词包括「chemotherapy」「vincristine」「prepubertal」「testis」「spermatogenesis」及相关术语。
  • 纳入标准:治疗时≤12岁、暴露于含长春新碱方案、长期生育结局;通过参考文献筛选补充研究。
  • 使用ROBINS-I工具评估偏倚,细分为混杂、参与者选择、干预分类、缺失数据、结局测量和报告结果选择。
  • 初始检索识别288篇文章,其中24篇(8%;n=7134名男性)符合所有纳入标准;9/24(38%)项研究有对照组,4/24(17%)项研究对长春新碱为基础药物的相对性腺毒性进行亚组分析。

主要发现

  • 对于进行长春新碱亚组分析的研究,无一项报告长春新碱与生育潜力呈负相关,包括最大的对照研究(n=6224;风险比=0.56)。
  • 一项研究(n=143)亚组分析显示,包括长春新碱在内的有丝分裂抑制剂与健康对照相比精液分析无显著差异。
  • 一项研究基于FSH水平和精液分析未发现长春新碱对精子发生有显著影响,意味着其给药不太可能是睾丸储备减少的原因;然而多数研究基于低数量接受含长春新碱化疗的患者。
  • 偏倚分析表明,进行长春新碱暴露亚组分析的研究与未进行亚组分析的队列相比偏倚风险更低。

关键数值与推荐

  • 主要结局指标为:生育力和为人父母;精液分析(世界卫生组织标准);激素功能和睾丸体积。
  • 最大对照研究(n=6224)中,长春新碱与生育潜力的风险比=0.56。
  • 一项研究(n=143)亚组分析中,包括长春新碱在内的有丝分裂抑制剂与健康对照相比精液分析无显著差异。
  • 一项研究基于FSH和精液分析未发现长春新碱对精子发生有显著影响。

临床怎么用

  • 有限的临床研究未显示青春期前暴露长春新碱后的性腺毒性作用,与近期啮齿动物研究结果相反。
  • 作者认为,鉴于缺乏长春新碱亚组分析的数据,需要使用人类睾丸组织进行长春新碱暴露的实验研究。
  • 作者认为,此类研究结果可更好地告知儿童癌症患者其未来生育力及治疗开始前生育力保存的资格。

局限性

  • 多数研究基于低数量接受含长春新碱化疗的患者。
  • 鉴于缺乏长春新碱亚组分析的数据,需要使用人类睾丸组织进行长春新碱暴露的实验研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing childhood cancer survival rates in recent decades have led to an increased focus on fertility as a long-term complication of cancer treatment. Male childhood cancer survivors often face compromised testicular function as a late effect of chemotherapy exposure, with no well-established options to prevent such damage and subsequent infertility. Despite vincristine being considered to be associated with low-gonadotoxic potential, in prepubertal rodents, it was recently shown to result in morphological alterations of the testis and in severely impaired fertility. OBJECTIVE AND RATIONALE: This systematic review aimed to evaluate the effects of vincristine-containing regimens on human prepubertal testis with reference to testicular function and fertility in adulthood. SEARCH METHODS: The systematic search of the literature was conducted according to PRISMA guidelines, and the study was registered with PROSPERO. PubMed and Scopus were searched for articles published in English between 01 January 1900 and 05 March 2021, with the search including 'chemotherapy', 'vincristine', 'prepubertal', 'testis', 'spermatogenesis' and related terms. Abstracts and full-text articles were screened and selected for, providing they met the inclusion criteria (≤12 years at treatment, exposure to vincristine-containing regimens and long-term fertility outcomes). Additional studies were identified via bibliography screening. Bias evaluation across included studies was conducted using the ROBINS-I tool, subdivided into assessment for confounding, participant selection, intervention classification, missing data, outcome measurements and selection of reported results. OUTCOMES: Our initial search identified 288 articles of which 24 (8%; n = 7134 males) met all inclusion criteria. Control groups were included for 9/24 (38%) studies and 4/24 (17%) studies provided sub-analysis of the relative gonadotoxicity of vincristine-based agents. Primary outcome measures were: fertility and parenthood; semen analysis (World Health Organization criteria); and hormonal function and testicular volume. For the studies that performed vincristine sub-analysis, none reported negative associations with vincristine for the potential of siring a pregnancy, including the largest (n = 6224; hazard ratio = 0.56) controlled study. For semen analysis, no significant difference versus healthy controls was illustrated for mitotic inhibitors (including vincristine) following sub-analysis in one study (n = 143). For hormone analysis, a single study did not find significant impacts on spermatogenesis attributed to vincristine based on levels of FSH and semen analysis, which meant that its administration was unlikely to be responsible for the diminished testicular reserve; however, most of the studies were based on low numbers of patients receiving vincristine-containing chemotherapy. Analysis of bias demonstrated that studies which included vincristine exposure sub-analysis had a lower risk of bias when compared with cohorts which did not. WIDER IMPLICATIONS: In contrast to recent findings in rodent studies, the limited number of clinical studies do not indicate gonadotoxic effects of vincristine following prepubertal exposure. However, given the relative lack of data from studies with vincristine sub-analysis, experimental studies involving vincristine exposure using human testicular tissues are warranted. Results from such studies could better inform paediatric cancer patients about their future fertility and eligibility for fertility preservation before initiation of treatment.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Clark I, Brougham MFH, Spears N, et al. The impact of vincristine on testicular development and function in childhood cancer. Hum Reprod Update. 2023. PMID: 36495566. doi:10.1093/humupd/dmac039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。